counterion comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-25. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are checked by reversed-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, where the peptide bond absorbs. Mass spectrometry confirms the expected mass and reveals whether truncation products or adducts are present. Acid hydrolysis followed by amino acid analysis gives the residue ratio, which should approximate one alanine, one glutamate, one aspartate and one glycine. Counter-ions such as acetate or trifluoroacetate remain in the dried product and lower net peptide content, so a stated purity figure on a label does not by itself describe how much peptide a vial holds.
Regulatory treatment differs by country. No formulation of epitalon holds a marketing authorisation as a medicine in the United States or the European Union, where material sold for laboratory use is handled as a research chemical and is not intended for human consumption. In Russia, several short peptide preparations from the same institute's peptide series are registered medicinal products, and epitalon appears in that national context. Elsewhere it is frequently offered as a cosmetic ingredient, a category with lighter requirements. Advertising claims about longevity or disease prevention are restricted in most jurisdictions, which limits how sellers describe the compound.
Freeze-dried epitalon is normally kept at minus twenty degrees Celsius in a sealed, desiccated container, protected from light. Short excursions at ambient temperature during shipping are generally tolerated, but repeated warming and cooling cycles encourage moisture uptake, which shortens shelf life. Once dissolved, the peptide is far less stable than the solid: aqueous solutions are subject to hydrolysis and to deamidation at the aspartate and glutamate residues. Working solutions are therefore held refrigerated and used within days, and repeated freezing and thawing of the same vial is best avoided.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection, frequently near 214 nanometers where the peptide bond absorbs. Mass spectrometry, most often with electrospray ionization, confirms the observed molecular mass and helps separate the intact peptide from truncated or modified forms. Amino acid analysis or tandem mass spectrometry can establish residue order. Purity is commonly quoted as an area percentage, yet such values are method-dependent, and comparisons between laboratories require matching column, gradient and detection wavelength.
Laboratory handling begins with dissolution of the lyophilized powder in water or a suitable aqueous buffer. The dry solid is the more stable form, so stock solutions are generally prepared only when required and kept cold afterwards. Repeated freezing and thawing of a solution is avoided because it encourages aggregation and gradual loss of the intact chain. Diluents and containers are selected to limit adsorption of a short peptide onto plastic surfaces and to reduce microbial growth in aqueous preparations.
Stability depends strongly on pH, temperature and the presence of oxygen and trace metals. Cleavage of the backbone proceeds faster under neutral to alkaline conditions, whereas acidic solutions tend to slow that reaction. The aspartate and glutamate side chains can undergo deamidation or imide formation over time, generating closely related impurities. Published stability data specific to epitalon are sparse, so the usable life of a given solution is best regarded as an open question that depends on buffer composition, concentration and storage temperature.
| Property | Value | Notes |
|---|---|---|
| Storage temperature, solid | Approximately -20 C | Sealed, desiccated, protected from light |
| Typical identity method | Electrospray mass spectrometry | Protonated ion expected near 391 |
| Typical purity method | Reversed-phase HPLC | Ultraviolet detection near 214 nm |
| Common synonyms | Epithalon, epithalone, AEDG | Spelling variants appear in supplier catalogues |
| Solution stability | Days at 2-8 C | Hydrolysis and deamidation limit shelf life |
Peptides of this size are generally stable as dry solids but degrade in solution over time. The principal routes are hydrolysis of the peptide backbone and oxidation, with hydrolysis favoured by elevated temperature and extreme pH. Aqueous solutions held at room temperature can show measurable loss of purity within days, while frozen aliquots are considerably more durable. Because the sequence contains neither cysteine nor methionine, oxidation is less of a concern than for many other peptides, but pH control during handling still matters.
Typical storage for the lyophilized powder is −20 °C or lower, in a sealed container protected from light and moisture. Hygroscopic material should be allowed to equilibrate to room temperature before the vial is opened, which limits condensation on the contents. Working solutions are commonly divided into single-use aliquots and frozen to avoid repeated freeze-thaw cycles. Dilute solutions are more prone to adsorption onto plastic surfaces and to loss during filtration, so procedures that minimize transfers and use low-binding labware are preferable.
From the earliest finds, opium has appeared to have ritual significance, and anthropologists have speculated ancient priests may have used the drug as a proof of healing power. In Egypt, the use of opium was generally restricted to priests, magicians, and warriors. Its invention is credited to Thoth, and it was said to have been given by Isis to Ra as treatment for a headache. A figurine of a goddess dated to around 1300 BC from the Minoan period contains three hairpins shaped as poppy capsules, all of which contain slits that suggest the Cretans knew the method of extracting opium. Additionally, her smile and parting lips suggests that she may be in a state induced by the opium. This has influenced some scholars to call her the "goddess of ecstasy". Further evidence confirms the use of opium in the Mediterranean since the Late Bronze Age due to a number of small lekythi from various places in Crete. These lekythi are supposed to have contained pharmaceutical opium due to the shape of the jars being analogous to those of the poppy head. Additionally, each jar is decorated with vertical stripes that are very similar to the process of cutting into the poppy to extract the sap. There is further evidence for the use of opium during this era due to painted pyxis. These would be decorated with painted poppy capsules and birds holding both poppy capsules and poppy stalks. Opium's use in the ancient Mediterranean world is well written about, with many authors discussing its uses.
== Veterinary use == BCG is used in England by licensed individuals to vaccinate wild badgers by trapping and release. It reduces new bovine TB infection rates by up to 76% in vaccinated badgers. It also exhibits a herd immunity effect, where a badger social group with more than one-third vaccination coverage shows up to 79% lower new infection in cubs. There is no evidence that vaccinated badgers excrete live BCG into the environment. Vaccination initiatives have been lead both by the government's Animal and Plant Health Agency and by private individuals and groups such as farmers seeking to protect their livestock and landowners seeking to clear their land of TB. BCG vaccination in cattle has completed a phase II trial in the UK with satisfactory results. The phase III trial started in 2025.
Upon rewarming, the kidney was transplanted successfully into a rabbit, with complete functionality and viability, able to sustain the rabbit indefinitely as the sole functioning kidney. In 2000, FM-2030 became the first person to be successfully vitrified posthumously.
== External links == Media related to Protons at Wikimedia Commons Particle Data Group at LBL Large Hadron Collider Eaves, Laurence; Copeland, Ed; Padilla, Antonio (Tony) (2010). "The shrinking proton". Sixty Symbols. Brady Haran for the University of Nottingham. MIT proton visualization project: Inside the Proton, the 'Most Complicated Thing You Could Possibly Imagine', Quanta Magazine, Oct 19 2022 Visualizing the Proton, Arts at MIT, 2022
=== The beginning of antibody imaging === Owing to their high affinity and specificity, antibodies have been considered as suitable vehicles for imaging and therapeutics, since the beginning of the 20th Century. The first radiolabelled antibodies were used in the early 1950s and got used for cancer therapy, but it took roughly two more decades before it was demonstrated that they target human tumour associated antigens in cancer patients. Due to the hybridoma technology in 1975, monoclonal (murine) antibodies could easily be produced in practical amounts, consequently the number of studies increased drastically. However, these types of antibodies turned out to be quite troublesome, due to the triggering of the human anti-murine antibody response. Consequently chimeric, humanised and human monoclonal antibodies have been created, produced and get used nowadays. Owing to the high molecular weight of antibodies and the Fc domain of the antibody, a slow clearance from the blood and non-target tissue occurs, which results in low tumour-to-blood and tumour-to-muscle ratios. Because of this, antibodies which are going to be used for imaging purposes need to be labelled with radionuclides that have a long half-life, which increases the radiation dose to the patient. This consequently encouraged the development of lower molecular weight antibodies and resulted in the development of minibodies, diabodies, single chain variable fragments (scFv) and single domain fragments (Fv).
Sources: en.wikipedia.org
=== First representation === A copper vaporizer block is electrically heated with two 100 watt cartridge heaters and a stainless steel capillary allow introduction of sample and consequent partial vaporization. The capillary and the vaporizer block are soldered together to ensure stable thermal contact. The resultant supersonic jet then passes through the ion source for introduction into the quadrupole mass spectrometer.
For services to Justice and to Human Rights in Hong Kong. Emma Walters, Head of Department, Foreign, Commonwealth and Development Office. For services to British Foreign Policy. Lieutenant Colonel (Rtd) Christopher Warren, Secretary General, Royal Commonwealth Ex-Services League. For services to Commonwealth Veterans. Colin Whorlow, Team Leader, Foreign, Commonwealth and Development Office. For services to National Security.
== Litigation == CLIA itself has not been the subject of much litigation. Federal district courts have held that the CLIA did not create a private cause of action for individuals to sue laboratories that do not comply with its provisions.
Amoxapine possesses a wide array of pharmacological effects. It is a moderate and strong reuptake inhibitor of serotonin and norepinephrine, respectively, and binds to the 5-HT2A, 5-HT2B, 5-HT2C, 5-HT3, 5-HT6, 5-HT7, D2, α1-adrenergic, D3, D4, and H1 receptors with varying but significant affinity, where it acts as an antagonist (or inverse agonist depending on the receptor in question) at all sites. It has weak but negligible affinity for the dopamine transporter and the 5-HT1A, 5-HT1B, D1, α2-adrenergic, H4, mACh, and GABAA receptors, and no affinity for the β-adrenergic receptors or the allosteric benzodiazepine site on the GABAA receptor. Amoxapine is also a weak GlyT2 blocker, as well as a weak (Ki = 2.5 μM, EC50 = 0.98 μM) δ-opioid receptor partial agonist. 7-Hydroxyamoxapine, a major active metabolite of amoxapine, is a more potent dopamine receptor antagonist and contributes to its neuroleptic efficacy, whereas 8-Hydroxyamoxapine is a norepinephrine reuptake inhibitor but a stronger serotonin reuptake inhibitor and helps to balance amoxapine's ratio of serotonin to norepinephrine transporter blockade.
== Development == A fruit results from the fertilizing and maturing of one or more flowers. The gynoecium, which contains the stigma-style-ovary system, is centered in the flower-head, and it forms all or part of the fruit. Inside the ovary(ies) are one or more ovules. Here begins a complex sequence called double fertilization: a female gametophyte produces an egg cell for the purpose of fertilization. (A female gametophyte is called a megagametophyte or embryo sac.) After double fertilization, the ovules become seeds. Ovules are fertilized in a process that starts with pollination, which is the movement of pollen from the stamens to the stigma-style-ovary system within the flower-head. After pollination, a pollen tube grows from the (deposited) pollen through the stigma down the style into the ovary to the ovule. Two sperm are transferred from the pollen to a megagametophyte. Within the megagametophyte, one sperm unites with the egg, forming a zygote, while the second sperm enters the central cell forming the endosperm mother cell, which completes the double fertilization process. Later, the zygote will give rise to the embryo of the seed, and the endosperm mother cell will give rise to endosperm, a nutritive tissue used by the embryo. Fruit formation is associated with meiosis, a central aspect of sexual reproduction in flowering plants. During meiosis homologous chromosomes replicate, recombine and randomly segregate, and then undergo segregation of sister chromatids to produce haploid cells.
Sources: en.wikipedia.org
The solid is kept cold, dry and dark, typically at minus twenty degrees Celsius, in a sealed container with desiccant. Dissolved material is kept refrigerated and used promptly. Freezing and thawing a solution repeatedly is avoided because it accelerates degradation.
Reversed-phase chromatography with ultraviolet detection gives a purity percentage, while mass spectrometry confirms identity. Amino acid analysis checks the residue composition. Buyers typically request a certificate of analysis showing these measurements for the specific lot.
It is not authorised as a medicine in the United States or the European Union. Material is sold there as a research chemical or cosmetic ingredient. Some related short peptides are registered drugs in Russia, which is a distinct national situation rather than a general approval.
The dry powder is typically held at -20 degrees Celsius or lower, protected from light and moisture. Allowing a sealed vial to reach room temperature before opening reduces condensation on its contents. Conditions stated on a supplier certificate of analysis take precedence over general guidance.